A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness based on the delivery of genetic material into the cells of the inner ear. The genetic material “replaces” the genetic defect and enables the cells to continue functioning normally.

The scientists were able to prevent the gradual deterioration of hearing in mice that had a genetic mutation for deafness. They maintain that this novel therapy could lead to a breakthrough in treating children born with various mutations that eventually cause deafness.

The study was led by Professor Karen Avraham of the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine and Sagol School of Neuroscience. The paper was published in EMBO Molecular Medicine on Dec. 22.

Deafness is the most common sensory disability worldwide. According to the World Health Organization, about half a billion people suffer hearing loss with this figure expected to double in the coming decades. One in every 200 children is born with a hearing impairment, and one in every 1,000 is born deaf. In about half of these cases, deafness is caused by a genetic mutation. There are currently about 100 different genes associated with hereditary deafness.